Edit here your fullwidth slider

VIVOS INC. (OTCQB: RDGL)

Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation.

Our Strategy: The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
Dr. Mike Korenko | President • CEO

CURRENT RELEASE

ViVOS, INc. Achieves important RadioGEL Development milestones

Richland WA, Jun. 24, 2020 (GLOBE NEWSWIRE) --

Vivos Inc. (OTCQB: RDGL), Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on completing the Radiogel™ Quality Management System (“QMS”). Our QMS validates that the pedigree of all future testing complies with the strict FDA guidelines. This week we initiated the biocompatibility testing contract as part of the previously defined pre-clinical testing. We are targeting to present our interim results to the FDA in a pre-submission meeting this year. This will set the stage for submittal of the Investigational Device Exemption (IDE). FDA approval of the IDE is required to begin clinical trials in humans. We believe that approval of the IDE will significantly enhance the potential partnering and licensing opportunities for Radiogel™.

>> Read Full Release

PRESS RELEASES

Click here for more news and updates

Stock Quote

Links

VIVOS Inc. (OTCQB: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com

Matrix themes

Documentation Quick setup Select a color Select a font Shortcodes Helper classes Updates Enterprise package Help Showcase Marketplace